The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB
Authors
Keywords
Multi-drug-resistant tuberculosis, Tuberculosis, Antimicrobial resistance, Drug therapy, Macrophages, Granulomas, Drug administration, Streptomycin
Journal
PLoS Computational Biology
Volume 12, Issue 3, Pages e1004749
Publisher
Public Library of Science (PLoS)
Online
2016-03-12
DOI
10.1371/journal.pcbi.1004749
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes
- (2013) Mai N. T. Huyen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of Drug Combinations against Mycobacterium tuberculosis Grown in Aerobic and Hypoxic Acidic Conditions
- (2013) Giovanni Piccaro et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Consequences of Noncompliance for Therapy Efficacy and Emergence of Resistance in Murine Tuberculosis Caused by the Beijing Genotype of Mycobacterium tuberculosis
- (2012) Jurriaan E. M. de Steenwinkel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
- (2012) Shama D. Ahuja et al. PLOS MEDICINE
- Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism
- (2011) Kristin N. Adams et al. CELL
- Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability
- (2011) Shashikant Srivastava et al. JOURNAL OF INFECTIOUS DISEASES
- Tuberculosis
- (2011) Stephen D Lawn et al. LANCET
- Effectiveness of the Standard WHO Recommended Retreatment Regimen (Category II) for Tuberculosis in Kampala, Uganda: A Prospective Cohort Study
- (2011) Edward C. Jones-López et al. PLOS MEDICINE
- Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis
- (2010) J. E. M. de Steenwinkel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
- (2009) T. Gumbo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hypoxia: a window intoMycobacterium tuberculosislatency
- (2009) Tige R. Rustad et al. CELLULAR MICROBIOLOGY
- Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance
- (2009) Indra L. Bergval et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis
- (2009) Dick Menzies et al. PLOS MEDICINE
- Influence of Multidrug Resistance on Tuberculosis Treatment Outcomes with Standardized Regimens
- (2008) Anton Mak et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Evaluation of Killing Kinetics of Anti-Tuberculosis Drugs on Mycobacterium tuberculosis Using a Bacteriophage-Based Assay
- (2008) Nimi Marcel et al. CHEMOTHERAPY
- Rate and Amplification of Drug Resistance among Previously‐Treated Patients with Tuberculosis in Kampala, Uganda
- (2008) Beth Temple et al. CLINICAL INFECTIOUS DISEASES
- Multidrug resistant to extensively drug resistant tuberculosis: What is next?
- (2008) Amita Jain et al. JOURNAL OF BIOSCIENCES
- Systems biology of persistent infection: tuberculosis as a case study
- (2008) Douglas Young et al. NATURE REVIEWS MICROBIOLOGY
- Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs
- (2008) G.R. Davies et al. TUBERCULOSIS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started